Advanced Enzyme Technologies Ltd

- Advanced Enzyme Technologies is investing in a new R&D center in Nasik (Pathardi area) on a 15-acre land acquired during COVID times. - The R&D building being constructed is around 120,000 square feet, approximately three times their current R&D capacity. - Planned R&D capital expenditure for the next two years is ₹30-40 crores. - The company is keeping cash reserves (~₹500 crores) available for potential strategic investments or business expansion opportunities. - Capital allocation includes continuous investments in R&D setup along with normal capital expenditures. - Mukund Kabra indicated expansion plans will be triggered when capacity utilization reaches around 80%, with a current utilization of about 65%. - Expansion will be done gradually in small increments to scale quickly as demand grows.

Future growth expectations for Advanced Enzyme Technologies Limited: - **Overall top-line growth:** Expected between 13% to 16% for FY'25 (Page 8, 18). - **Human nutrition segment:** Anticipated to grow with continued contributions from the US and domestic markets; expected to stabilize between 65%-70% of total business mix over the next 2-3 years (Pages 7, 18). - **US market:** Growth driven by new products in weight and sugar management with 9% growth in FY'24 and positive outlook for FY'25 (Pages 8, 18). - **Bioprocessing segment:** Grew 21% in FY'24; expected decent growth due to new product launches (Page 4, 14). - **Animal nutrition:** Volatile with challenges; 5% decline in FY'24, but expected to stabilize with industry dynamics (Pages 4, 16, 18). - **Product pipeline and R&D:** Significant investment in new R&D facilities (~₹30-40 crores over two years) to drive future innovation and growth (Page 16). - **Probiotics business:** Growth potential linked to combined enzyme-probiotics formulations, though specific targets are unclear (Page 18).

- The company expects double-digit top-line growth, targeting around 13% to 16% CAGR going forward (Pages 7, 9, 18). - EBITDA margin is expected to improve gradually, with a steady-state margin around 33% annually, up from 29% in FY'23 and 33% in FY'24 (Pages 9, 18). - Margin expansion is anticipated as growth picks up, especially with improvements expected from the US business and product mix (Pages 7, 8, 18). - Earnings growth driven by increased revenues, better product mix, strong cost control, and higher other income as noted in recent quarters (Pages 4, 5, 9). - New R&D investments (~₹30-40 crores over two years) and product pipeline expansion expected to support sustainable growth (Page 16). - Probiotics and other high-potential areas expected to contribute, though precise margin impact is unclear (Page 18). - The animal nutrition segment may see normal pharma-industry-like growth but remains challenging due to competitive pressures (Page 16).

- The company does not maintain a formal order book or pending orders. - Business operates on an order-to-order basis based on customer needs and market demand. - It is difficult to predict exact revenue numbers or future order flow quarter-to-quarter. - Customers and orders are somewhat known but there is no structured long-term contract backlog. - This approach reflects the nature of the enzyme and bioproducts industry, which is demand-driven and flexible.

- The transcript does not mention any current or planned fundraising through debt or equity. - The company has about ₹500 crores of cash on the balance sheet and generates around ₹100 crores of cash annually. - Capital allocation strategy includes dividends and keeping cash reserves for potential opportunities and business expansion. - The company is also investing around ₹30-40 crores over the next two years in developing new R&D centers. - No specific plans or announcements related to raising debt or equity funding were discussed in the call.